Lentiviral vectors are widely used for stable gene delivery because they can transduce both dividing and non-dividing cells, enabling long-term transgene expression. But whether you’re running basic research or advancing a cell and gene therapy program, you need a titration method that is precise, reproducible, and transferable—especially when decisions like multiplicity of infection (MOI), dose selection, and product release depend on it.
Traditional qPCR-based lentiviral titration can be slow and calibration-heavy. Accurate quantification typically requires a standard curve built from a control template with a known copy number, and results can be sensitive to amplification efficiency, inhibitors, and operator-to-operator variability. These challenges become more pronounced when sample input is limited or DNA quality is suboptimal.
To solve this, we implemented a TaqMan-based QuantStudio Absolute Q digital PCR (dPCR) workflow that quantifies integrated proviral DNA in transduced cells, delivering a precise, standard-curve-free measure of vector copy number (VCN) to support lentiviral titration and MOI decisions. The workflow partitions each sample into thousands of individual PCR microreactions, some containing the target (positive) and others not (negative), then uses the fraction of negative partitions to calculate absolute copy number via Poisson statistics. To solve this, we implemented a TaqMan-based QuantStudio Absolute Q digital PCR (dPCR) workflow for functional lentiviral titration by measuring integrated proviral DNA in transduced cells. dPCR works by partitioning a sample into thousands of individual PCR microreactions: some contain the target (positive) and others do not (negative). After endpoint amplification, the fraction of negative partitions is used to calculate absolute copy number using Poisson statistics—delivering direct quantification without a standard curve.
The more biologically meaningful readout of lentiviral transduction is not “how much viral genome is present,” but how many proviral DNA copies are integrated per cell commonly reported as vector copy number (VCN). Measuring VCN provides a direct view of transduction performance and supports rational selection of MOI without relying solely on proxy readouts such as fluorescence.
Our approach combined the strengths of both platforms:
This target + reference strategy supports accurate copies-per-cell calculations and reduces sample-to-sample variability caused by differences in input DNA. A one-step dPCR workflow (e.g., ViralSEQ dPCR Lentivirus Physical Titer Kit, Thermo Fisher Scientific) streamlines determination of copy number across serial dilutions and confirm the quantitative range.
Why dPCR improves lentiviral titration:
We developed a reliable, transferable multiplex TaqMan Absolute Q dPCR assay for lentiviral titration using proviral DNA + RNase P. This workflow delivers endpoint absolute quantification of integrated lentiviral genomes, reducing calibration burden and minimizing susceptibility to run-to-run variation.
By enabling accurate determination of infectious titer, MOI optimization, and vector copy number (VCN), the assay provides critical process and product insights for lentiviral vector manufacturing and gene-modified cell therapy development. These metrics support:
Overall, this case study supports digital PCR (dPCR) as a powerful tool for lentiviral infectious titer and VCN determination, helping advance cell and gene therapy programs targeting diseases such as cancer, HIV, cardiovascular disorders, neurodegenerative diseases, and asthma through more onsistent, data-driven development decisions.